FYB206 is being reviewed as a pembrolizumab biosimilar after meeting pharmacokinetic equivalence; no additional efficacy trial is required.
|Articles|August 18, 2014
- Immunotherapy (Issue 3)
- Volume 3
- Issue 1
Future Immune Checkpoint Strategies
Author(s)James P. Allison, PhD
James P. Allison, PhD, director, immunotherapy platform, The University of Texas MD Anderson Cancer Center, discusses the future of immune checkpoint strategies.
Advertisement
James P. Allison, PhD, director, immunotherapy platform, The University of Texas MD Anderson Cancer Center, discusses the future of immune checkpoint strategies.
Learn about the history of immunotherapy > >
Articles in this issue
about 12 years ago
A Brief History of Immunotherapyabout 12 years ago
Better Biomarker Testing Needed in Immuno-Oncologyabout 12 years ago
Autoimmunity and Limitations of Cancer Vaccinesabout 12 years ago
The Management of Side Effects Associated With Immunotherapiesabout 12 years ago
The Next Wave in Immunotherapy: CombinationsAdvertisement
Related to this article
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5